Leerink Partners Remains Bullish as Trillium Therapeutics (TRIL) Continues TTI-621 Development
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
Trillium Reports 2015 Financial and Operating Results
March 9, 2016 5:31 PM ESTTORONTO, ONTARIO -- (Marketwired) -- 03/09/16 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reports financial results for the year ended December 31, 2015 and provides a corporate update.
"2015 was a pivotal year for Trillium with the successful advancement of TTI-621, our checkpoint inhibitor targeting CD47, into human clinical trials in patients with advanced hematologic malignancies and we look forward to providing an update on this trial by the end of this year," commented Trillium's Chief Executive... More
Trillium to Present at the Cowen and Company 36th Annual Health Care Conference
March 8, 2016 7:01 AM ESTTORONTO, ONTARIO -- (Marketwired) -- 03/08/16 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that Bob Uger, Ph.D., Chief Scientific Officer will present at the Cowen and Company 36th Annual Health Care Conference at The Boston Marriott Copley Place in Boston, MA on Wednesday, March 9th at 11:20 am.
Webcast Information:
The live webcast of the presentation will be accessible from the following website:... More
